Cromwell Holdings’s Charles River Laboratories CRL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$56.6K Buy
192
+7
+4% +$1.84K 0.03% 457
2026
Q2
$42K Buy
185
+5
+3% +$890 0.02% 514
2026
Q1
$31.1K Hold
180
– – 0.02% 525
2025
Q4
$35.9K Hold
180
– – 0.02% 511
2025
Q3
$28.2K Hold
180
– – 0.02% 553
2025
Q2
$27.3K Buy
180
+152
+543% +$20.3K 0.02% 543
2025
Q1
$4.21K Sell
28
-39
-58% -$6.54K ﹤0.01% 607
2024
Q4
$12.4K Sell
67
-80
-54% -$15.4K 0.01% 597
2024
Q3
$29K Hold
147
– – 0.02% 542
2024
Q2
$30.4K Buy
+147
New +$33.3K 0.02% 529

Other funds holding CRL

Cromwell Holdings's CRL Position: Q3 2026 in Review

Cromwell Holdings increased its Charles River Laboratories (CRL) stake by 3.8% in Q3 2026, buying an estimated $1.84K and bringing the position to 192 shares worth $56.6K. The position accounts for 0.03% of the portfolio, ranked #457.

Cromwell Holdings first reported a position in CRL in Q2 2024 and has held it in 10 quarters since. 646 funds tracked by Wall St. Rank hold CRL as of Q3 2026.

  • Cromwell Holdings held 192 shares of Charles River Laboratories worth $56.6K as of Q3 2026.
  • Cromwell Holdings bought 7 Charles River Laboratories shares in Q3 2026, an estimated $1.84K.
  • Charles River Laboratories made up 0.03% of Cromwell Holdings's portfolio in Q3 2026, its #457 holding.
  • Cromwell Holdings first reported a position in Charles River Laboratories in Q2 2024 and has held it in 10 quarters since.
  • 646 funds tracked by Wall St. Rank held Charles River Laboratories as of Q3 2026.

Based on Cromwell Holdings's 13F filing for Q3 2026, filed 28 Oct 2026.